Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

EXPLAINED: Looking into mersana therapeutics s return on capital employed | Rare Historical Photos

Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 7.72%, resulting in a loss of $48.98 million. Mersana Therapeutics collected $11.00 thousand in revenue during Q3, but reported earnings showed a $45.47 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.